Same drug — semaglutide — in two forms. Rybelsus is a daily pill; Ozempic is a once-weekly injection. Both are made by Novo Nordisk and approved for type 2 diabetes.
| Rybelsus | Ozempic | |
|---|---|---|
| Active drug | semaglutide | semaglutide |
| Drug class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| FDA-approved for | Type 2 diabetes | Type 2 diabetes |
| How it's taken | Once-daily oral tablet | Once-weekly injection |
| Maker | Novo Nordisk | Novo Nordisk |
Rybelsus and Ozempic are the same active medicine — semaglutide, from Novo Nordisk — both approved for type 2 diabetes. The headline difference is how you take it: Rybelsus is the oral tablet (the first GLP-1 in a pill), and Ozempic is the weekly injection.
Rybelsus is a once-daily tablet that must be taken on an empty stomach with a small sip of water, then wait before eating or other medicines — absorption is finicky. Ozempic is a once-weekly injection. Same molecule and approved use (type 2 diabetes); the choice is often about needle preference, daily-vs-weekly routine, and coverage. Neither is FDA-approved for weight management — Wegovy is the weight-approved semaglutide brand.
Both deliver semaglutide, but the oral and injectable forms reach the body differently, so doses aren't directly interchangeable milligram-for-milligram. Weight loss is a secondary effect at diabetes doses for both. These are general statements, not a promise — dosing and results are individualized. This is general information, not medical advice.
Rybelsus (pill) and Ozempic (weekly injection) are the same drug, semaglutide, for type 2 diabetes. Pick based on whether you'd rather take a daily tablet (with its empty-stomach rules) or a weekly shot — a clinician sets the equivalent dose. Not medical advice.
General information, not medical advice, and not a substitute for your clinician. Efficacy figures are pivotal-trial averages — individual results, side effects, and cost vary. Only a licensed healthcare professional can choose, start, switch, or dose these medicines.